EDUCATION
Utility of Cell-free DNA in the Clinic: Current State and Future Directions
This eight-part webcast series on liquid biopsy titled, “Utility of Cell-free DNA in the Clinic: Current State and Future Directions.” will cover a range of concepts from the basic biological underpinnings of cell-free DNA (cfDNA) to new and specific advances (and the clinical implications thereof) in the diagnostic and prognostic use of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). These eight webcasts will occur every 2-3 months, beginning in May, 2021.
In addition to the eight hour-long webinars, a series of “Molecular in a Minute” micro-learning modules will be recorded. These will cover new topics, advances, and applications for liquid biopsy in the laboratory and in the clinic. Links coming soon.
After broadcast, each webinar and Molecular in a Minute module will be posted on the AMPEDTM online Learning Management System. Keep checking back here for additional content and information.
LEARNING OBJECTIVES
Following the full program, participants will be able to:
- Describe the components of Cell-free DNA (cfDNA), and its dynamics in health and disease.
- Identify challenges, and list possible solutions, unique to cfDNA assay validation.
- Discuss opportunities of Circulating Tumor DNA (ctDNA) assessment in oncology practices.
- Discuss limitations of ctDNA assessment in oncology practices.
- Summarize current standards and practices in NIPS
- Recognize opportunities and pitfalls of non-invasive microbial assessment
- Describe the possible roles for novel circulating analytes in oncology.
- Discuss the unique advantages and disadvantages of alternate sources of cfDNA.
View bundle of all 8 webinars
Schedule:
Webinar #1: Basic Biology and Detection of Cell-Free DNA
Speakers: Rena Xian, MD and Lynette M. Sholl MD
Date: May 18th, 2021
Webinar #2: Practical Analytical and Clinical validation Strategies for Cell-Free Tumor DNA Assays
Speaker: Christina Lockwood, PhD
Date: July 27, 2021
Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers
Speaker: Everett Moding, MD PhD
Date: September 28, 2021
Webinar #4: Cell free (cf)DNA-based Prenatal Screening: Lessons Learned and Future Strategies
Speaker: Glenn Palomaki, PhD
Date: January 6, 2022
Webinar #5: Current and Emerging Applications of cell-free DNA Tumor Tests
Speaker: Keyur Patel, MD, PhD
Date: March 24, 2022
Webinar #6: Cell-free DNA: predictive tissue injury maps in COVID-19
Speaker: Sean Agbor-Enoh, MD, PhD
Date: August 9, 2022
Webinar #7: Utility of Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Infections
Speaker: Charles Chiu, MD, PhD
Date: December 13, 2022
Webinar #8: Hereditary Cancer Surveillance Using Cell-free DNA Sequencing
Speaker: Trevor Pugh, PhD, FACMG
Date: February 2, 2023
Molecular in a Minute:
ctDNA Sequencing: A strategy for treatment response monitoring of aggressive B cell lymphoma
Description: This module will summarize the current knowledge related to circulating tumor DNA in patients with aggressive B cell lymphoma, such as diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and discuss how ctDNA measurements can be used to monitor treatment response in the front-line setting.
Speaker: Rena Xian, MD
Length: 13 min
Recorded: May 18, 2021
How Accurate is That Test? Quality Assessment for Cell-Free DNA Tumor Tests
Description: This module summarizes laboratory error detection and reviews current quality monitoring for clinical laboratories performing cell-free tumor DNA tests.
Speaker: Christina Lockwood, MD
Length: 15 min
Recorded: July 21, 2021
Choosing the best circulating tumor DNA assay for your clinical application: technical and analytical considerations
Description: Dr. Moding discusses the fundamental differences between currently available circulating tumor DNA assays to help clinicians choose the best assay for their application.
Speaker: Everett Moding, MD
Length: 8 min
Recorded: September 23, 2021
Assessment of Laboratories offering cell free (cf)DNA screening for Down syndrome
Description: The CAP offers a bi-yearly external educational exercise for laboratories offering cfDNA based prenatal screening for common aneuploidies based on three clinical scenarios and results of testing prepared samples. A brief review of these results will include computation of maternal and gestational age as well as clinical results such as z-scores, clinical interpretation, assessing fetal sex and fetal fraction.
Speaker: Glenn E. Palomaki, PhD
Length: 13 min
Recorded: January 6, 2021
Error-Correction Strategies in NGS
Description: Dr. Patel discusses the error-correction strategies in NGS.
Speaker: Keyur Patel, MD
Length: 22 min
Recorded: March 24, 2022
Early Detection of Transplant Rejection Using cfDNA
Description: Dr. Agbor-Enoh discusses the Early Detection of Transplant Rejection Using cfDNA.
Speaker: Sean Agbor-Enoh, MD, PhD
Length: 6 min
Recorded: August 9, 2022
Calibration of Cell-Free DNA Measurements to Monitor Disease Burden in Cancer or Infectious Disease Patients
Description: Dr. Gulley discusses the Calibration of Cell-Free DNA Measurements to Monitor Disease Burden in Cancer or Infectious Disease Patients.
Speaker: Peggy Gulley, MD
Length: 14 min
Recorded: January 27, 2023
Personalized cell-free DNA testing to predict and monitor response to cancer immunotherapy
Description: Dr. Pugh discusses the Personalized cell-free DNA testing to predict and monitor response to cancer immunotherapy.
Speaker: Trevor Pugh, MD, FACMG
Length: 10 min
Recorded: February 2, 2023
Physicians (ACCME)
.jpg)
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live to enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM (1.00 CE for each webinar). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Laboratory Education (CMLE)
This activity has been planned and implemented in accordance with the Amedco and joint provider-ship of the ASC and the Association for Molecular Pathology (AMP). Course number 7013.
This webinar series on Utility of Cell-Free DNA in the Clinic is planned and coordinated by the Liquid Biopsy Content Committee:
|
Rena Xian, MD, Content Chair |
Marjorie Parker David, MD, MS |
Margaret L. Gulley, MD |
|
|
|
And supported by the AMP Training & Education Committee (Nathanael G. Bailey, MD, Chair)
This activity is supported by educational funding provided by Amgen and AstraZeneca.
Instructions for Accessing Live and On-Demand Webinars from AMP (PDF)
